摘要
目的探讨血必净联合乌司他丁治疗重症急性胰腺炎的疗效和安全性。方法将95例重症急性胰腺炎患者随机分成对照组(48例)和治疗组(47例)。对照组在常规治疗基础上加用乌司他丁20万U,1次/12 h,静脉滴注;治疗组在上述治疗基础上加用血必净注射液100 m l,1次/12 h,静脉滴注。比较2组患者腹痛缓解时间、体征减轻时间、血尿淀粉酶恢复正常时间、白细胞计数恢复时间、平均住院时间、并发症发生率、中转手术率和死亡率。结果治疗7 d后,治疗组和对照组腹痛缓解时间[(4.2±1.6)和(6.5±2.4)d]、血及尿淀粉酶恢复时间[(4.7±1.6)及(5.5±1.3)d,(7.6±2.8)及(7.9±2.3)d]、白细胞计数恢复时间[(7.2±4.1)和(10.8±2.6)d]、平均住院时间[(22.4±3.9)和(30.5±3.5)d]及体征减轻时间[(4.5±1.9)和(6.2±1.5)d]间差异均有统计学意义(P<0.05);治疗组并发症发生率、中转手术率与对照组间差异有统计学意义(χ2=4.71和5.16,P<0.05);两组组死亡率间差异无统计学意义(χ2=2.76,P>0.05)。结论血必净联合乌司他丁治疗重症急性胰腺炎较常规治疗组可及早改善患者的症状、体征和各项实验室指标,减少并发症发生率和中转手术率,其疗效明确,安全性高,此方法是值得推荐的。
Objective To investigate the effectiveness and safety of Xuebijing combined with ulinastatin in treating severe acute pancreatitis.Methods Totally 95 patients with severe acute pancreatitis were randomly divided into control group（conventional therapy plus ulinastatin;n=48） and Xuebijing group（conventional therapy plus ulinastatin plus Xuebijing;n=47）.Ulinastatin was intravenously administered 200 000 Units twice daily for 7 days;Xuebijing was intravenously injected 100 mL twice daily for 7 days.The outcomes were compared between these two groups.Results Seven days after treatment,the alleviative time of abdominal pain（4.2±1.6）和（6.5±2.4）d],recovery time of blood/urine amylase[（4.7±1.6） and（5.5±1.3）d vs（7.6±2.8）and（7.9±2.3）d],recovery time of white blood cell[（7.2±4.1）和（10.8±2.6）d],mean hospital stay[（22.4±3.9） and（30.5±3.5）d],and alleviative time of symptoms[（4.5±1.9）和（6.2±1.5）d]were significantly different between control group and Xuebijing group.The incidence of complications and surgical conversion rate were significantly lower in Xuebijing group（P0.05）,while the mortality rate was not significantly different（P0.05）.Conclusion Xuebijing combined with ulinastatin can improve the symptoms and laboratory results of the patients with severe acute pancreatitis and reduce complications and surgical conversion.
出处
《中国全科医学》
CAS
CSCD
北大核心
2010年第24期2670-2671,共2页
Chinese General Practice
